S&P 500   4,691.25 (+2.17%)
DOW   35,754.77 (+1.50%)
QQQ   397.94 (+3.04%)
AAPL   171.07 (+3.48%)
MSFT   335.56 (+2.87%)
FB   324.14 (+1.97%)
GOOGL   2,937.31 (+2.59%)
AMZN   3,528.73 (+2.96%)
TSLA   1,043.50 (+3.42%)
NVDA   320.58 (+6.73%)
BABA   125.79 (+1.77%)
NIO   33.31 (+3.00%)
CGC   10.88 (+7.19%)
AMD   145.19 (+4.41%)
GE   98.01 (+2.08%)
MU   86.86 (+5.35%)
T   23.14 (-0.60%)
F   19.91 (+3.59%)
DIS   150.67 (+0.20%)
PFE   51.33 (-0.29%)
AMC   31.25 (+8.54%)
ACB   6.42 (+7.54%)
BA   210.42 (+2.21%)
S&P 500   4,691.25 (+2.17%)
DOW   35,754.77 (+1.50%)
QQQ   397.94 (+3.04%)
AAPL   171.07 (+3.48%)
MSFT   335.56 (+2.87%)
FB   324.14 (+1.97%)
GOOGL   2,937.31 (+2.59%)
AMZN   3,528.73 (+2.96%)
TSLA   1,043.50 (+3.42%)
NVDA   320.58 (+6.73%)
BABA   125.79 (+1.77%)
NIO   33.31 (+3.00%)
CGC   10.88 (+7.19%)
AMD   145.19 (+4.41%)
GE   98.01 (+2.08%)
MU   86.86 (+5.35%)
T   23.14 (-0.60%)
F   19.91 (+3.59%)
DIS   150.67 (+0.20%)
PFE   51.33 (-0.29%)
AMC   31.25 (+8.54%)
ACB   6.42 (+7.54%)
BA   210.42 (+2.21%)
S&P 500   4,691.25 (+2.17%)
DOW   35,754.77 (+1.50%)
QQQ   397.94 (+3.04%)
AAPL   171.07 (+3.48%)
MSFT   335.56 (+2.87%)
FB   324.14 (+1.97%)
GOOGL   2,937.31 (+2.59%)
AMZN   3,528.73 (+2.96%)
TSLA   1,043.50 (+3.42%)
NVDA   320.58 (+6.73%)
BABA   125.79 (+1.77%)
NIO   33.31 (+3.00%)
CGC   10.88 (+7.19%)
AMD   145.19 (+4.41%)
GE   98.01 (+2.08%)
MU   86.86 (+5.35%)
T   23.14 (-0.60%)
F   19.91 (+3.59%)
DIS   150.67 (+0.20%)
PFE   51.33 (-0.29%)
AMC   31.25 (+8.54%)
ACB   6.42 (+7.54%)
BA   210.42 (+2.21%)
S&P 500   4,691.25 (+2.17%)
DOW   35,754.77 (+1.50%)
QQQ   397.94 (+3.04%)
AAPL   171.07 (+3.48%)
MSFT   335.56 (+2.87%)
FB   324.14 (+1.97%)
GOOGL   2,937.31 (+2.59%)
AMZN   3,528.73 (+2.96%)
TSLA   1,043.50 (+3.42%)
NVDA   320.58 (+6.73%)
BABA   125.79 (+1.77%)
NIO   33.31 (+3.00%)
CGC   10.88 (+7.19%)
AMD   145.19 (+4.41%)
GE   98.01 (+2.08%)
MU   86.86 (+5.35%)
T   23.14 (-0.60%)
F   19.91 (+3.59%)
DIS   150.67 (+0.20%)
PFE   51.33 (-0.29%)
AMC   31.25 (+8.54%)
ACB   6.42 (+7.54%)
BA   210.42 (+2.21%)
NASDAQ:NRXP

NRx Pharmaceuticals Stock Forecast, Price & News

$6.26
+0.31 (+5.21%)
(As of 12/7/2021 12:55 PM ET)
Add
Compare
Today's Range
$5.83
$6.47
50-Day Range
$4.50
$11.91
52-Week Range
$4.07
$76.99
Volume
33,617 shs
Average Volume
2.51 million shs
Market Capitalization
$368.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.35
30 days | 90 days | 365 days | Advanced Chart
Receive NRXP News and Ratings via Email

Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About NRx Pharmaceuticals

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Headlines

Why NRx Pharmaceuticals Stock Soared Today
November 29, 2021 |  fool.com
Why Are NRx Pharma's Shares Soaring Premarket?
November 29, 2021 |  markets.businessinsider.com
NRx Pharmaceuticals (NASDAQ:NRXP) Shares Gap Up to $6.75
November 29, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NRXP
Fax
N/A
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.15 per share

Profitability

Net Income
$-1.09 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
47,924,000
Market Cap
$368.15 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/16/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/15/2022

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

1149th out of 1,394 stocks

Pharmaceutical Preparations Industry

552nd out of 673 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












NRx Pharmaceuticals (NASDAQ:NRXP) Frequently Asked Questions

Are investors shorting NRx Pharmaceuticals?

NRx Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 1,180,000 shares, a decrease of 29.3% from the October 31st total of 1,670,000 shares. Based on an average trading volume of 2,740,000 shares, the short-interest ratio is presently 0.4 days. Approximately 5.1% of the shares of the company are short sold.
View NRx Pharmaceuticals' Short Interest
.

When is NRx Pharmaceuticals' next earnings date?

NRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for NRx Pharmaceuticals
.

How were NRx Pharmaceuticals' earnings last quarter?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced its quarterly earnings results on Tuesday, November, 16th. The company reported ($0.39) earnings per share for the quarter.
View NRx Pharmaceuticals' earnings history
.

Who are NRx Pharmaceuticals' key executives?

NRx Pharmaceuticals' management team includes the following people:
  • Jonathan C. Javitt, Chairman & Chief Executive Officer
  • Robert Besthof, Chief Commercial & Patent Officer, Head-Operations (LinkedIn Profile)
  • James Brandon, Chief Financial Officer
  • Dennis K. McBride, Chief Strategy Officer
  • Randy Guggenheimer, Chief Business Officer

What is NRx Pharmaceuticals' stock symbol?

NRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "NRXP."

Who are NRx Pharmaceuticals' major shareholders?

NRx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Citadel Advisors LLC (0.00%), Cambridge Investment Research Advisors Inc. (0.29%), Geode Capital Management LLC (0.09%), Jane Street Group LLC (0.00%), Advisor Group Holdings Inc. (0.08%) and Wolverine Asset Management LLC (0.08%). Company insiders that own NRx Pharmaceuticals stock include Alessandra Daigneault and Robert Besthof.
View institutional ownership trends for NRx Pharmaceuticals
.

Which major investors are buying NRx Pharmaceuticals stock?

NRXP stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Cambridge Investment Research Advisors Inc., Jane Street Group LLC, Advisor Group Holdings Inc., Wolverine Asset Management LLC, Geode Capital Management LLC, Penserra Capital Management LLC, and Clear Street Markets LLC.
View insider buying and selling activity for NRx Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of NRx Pharmaceuticals?

Shares of NRXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NRx Pharmaceuticals' stock price today?

One share of NRXP stock can currently be purchased for approximately $6.21.

How much money does NRx Pharmaceuticals make?

NRx Pharmaceuticals has a market capitalization of $365.21 million.

How many employees does NRx Pharmaceuticals have?

NRx Pharmaceuticals employs 2 workers across the globe.

What is NRx Pharmaceuticals' official website?

The official website for NRx Pharmaceuticals is www.bigrockpartners.com.

Where are NRx Pharmaceuticals' headquarters?

NRx Pharmaceuticals is headquartered at 2645 N. Federal Highway Suite 230, Delray Beach FL, 33483.

How can I contact NRx Pharmaceuticals?

NRx Pharmaceuticals' mailing address is 2645 N. Federal Highway Suite 230, Delray Beach FL, 33483. The company can be reached via phone at (484) 254-6134.


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.